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they inhibited 75% of the thymidine uptake,
when taken from PM cultures with as little as
0.5%0 foetal bovine serum. Further, it was
found that sera from various species could
produce this macrophage activation. The
supernatant of 72 h cultured PM contained
a cytostatic factor (CF) which could inhibit
50-75% of the thymidine incorporation in
equal number of HPM cells. CF was found
to be thermostable and dialysable.
These findings suggest that some normal
serum components could substitute in vitro
for the in vivo activation of PM.
DEMONSTRATION OF THE ANTI-
TUMOUR EFFECT OF IN VIVO
MACROPHAGE ACTIVATION. I. PARR.
Chester Beatty Research Institute, Sutton,
Surrey.
Macrophages from mice sensitized to one
antigen become nonspecifically cytotoxic to
tumour cells after meeting the same antigen
again (Evans and Alexander, Nature, Lond.,
1972, 236, 168). This transformation was
termed macrophage activation. Where a
condition of chronic infection has become
established, persistence of the infecting
antigen can lead to the presence of activated
macrophages (Hibbs, Lambert and Remming-
ton, J. infect. Dis., 1971, 124, 587). No
activated macrophages couldbedemonstrated
in the peritoneal cavities of mice that had
been injected i.p. with B.C.G. 2 weeks
previously. This may be a reflection of the
fact that the strain of B.C.G. (Glaxo) that
was used does not persist in large numbers in
the peritoneal cavities of mice. Reintroduc-
tion of the antigen (as PPD) into the same
site as the tumour cells protected against
syngeneic tumour challenge with either
lymphoma (L5178Y in DBA/2 mice) or
fibrosarcoma (FS6inC57B1 mice). Peritoneal
exudate (PE) cells from B.C.G. sensitized mice
could be made cytotoxic to fibrosarcoma
cells by re-addition of the antigen.
IMMUNOLOGICAL DEPLETION
CONTRIBUTING TO FAMILIAL
HODGKIN'S DISEASE. J. J. FENELLY
and A. McBRIDE. St Vincent's Hospital,
Dublin.
In a family of 5 girls, 3 of whom have
Hodgkin's disease, pathogenetic possibilities
were studied, i.e. HL-A typing, chromosomes,
detailed blood group analysis, humoral anti-
body (immunoglobulins, serum protein
electrophoresis), cell mediated immunity
(PPD, DNCB, LTT and MLC), viral studies
(Epstein-Barr, other herpesviruses, CMV)
Australia antigen.
The major abnormality was a defect of
cell mediated immunity detected in both
parents and the 5 girls as evidenced by
very poor in vitro lymphocyte blastogenesis
with PHA in all 7. The fourth sister (recent
infectious mononucleosis), and the mother,
were anergic to PPD and DNCB while the
father and fifth sister (recurrent herpes
labialis) both had 4+ DNCB, reaction. In
addition, the mother had an M band on serum
protein electrophoresis.
Our findings suggest that a familial cell
mediated immune depletion is providing a
milieu wherein viral infection may manifest
itself as Hodgkin's disease.
SOME ASPECTS OF THE USE OF
B.C.G. IN THE TREATMENT OF
ADVANCED MALIGNANT DISEASE.
R. M. GRANT, R. M. MACKIE, A. J. COCHRAN,
D. HOYLE and C. Ross. Departments of
Pathology and Dermatology, Western Infir-
mary, Glasgow.
We have usedB.C.G. (Glaxopercutaneous)
in the treatment of 7 patients with advanced
malignant disease.
One patient with malignant melanoma
showed regression of more than 70 B.C.G.
injected subcutaneous metastases: the rate
at which new deposits developed declined
and there was only minimal spread to internal
organs. Intra-tumoral B.C.G. was followed
by regression and eventual sloughing of
approximately 90% of an extensive fun-
gating tumour in a patient with local re-
currence of breast cancer in the mastectomy
scar. Local reaction to intratumoral B.C.G.,
without retardation in the progression of the
disease, was observed in a patient with
malignant melanoma while prolongation of
survival was noted in another patient who
had a large solitary lung metastasis. There
was no detectable response to B.C.G. in the
remaining 3 cases.
Pyrexia, lassitude and anorexia occurred
as transient side-effects of B.C.G. therapy in
3 patients. One patient experienced a severe
generalized B.C.G. infection.